China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients ...
Business Wire3d
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obe…
Laekna, Inc. (2105.HK) (“Laekna”), a global biotech company focused on novel drug development for metabolic and cancer ...
Laekna, Inc. Announces Share Placement to Raise HK$230 Million
Laekna, Inc. (HK:2105) has released an update.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top Wall Street ...
The Pharma Letter2d
Lilly and Laekna team up on novel obesity drugs
Eli Lilly has partnered with Laekna to advance LAE102, an antibody targeting the ActRIIA receptor, for obesity and muscle ...
阿思達克財經網3d
LAEKNA-B Last Slumps 7%+ after Announcing Shr Placing on 48% Rally Ytd
LAEKNA-B (02105.HK) announced a share placing immediately after a 48% share surge yesterday (20th). Today (21st), it opened ...
Laekna Partners with Eli Lilly on Obesity Drug Development
Laekna, Inc. (HK:2105) has released an update.Don't Miss out on Research Tools:Discover the latest stocks recommended by top Wall Street ...
U.S. News & World Report3d
China-Based Biotech Laekna Teams up With Lilly to Develop Muscle Preserving Obesity Drug
(Reuters) - Eli Lilly and Hong Kong-listed Laekna will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle, the biotech said on ...
Yahoo Finance3d
China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
(Reuters) - Eli Lilly (LLY) and Hong Kong-listed Laekna (2105.HK) will collaborate to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle ...
BioSpace2d
Lilly Partners With Chinese Biotech to Advance Muscle-Sparing Obesity Treatment
Lilly will provide the funding and expertise to advance Laekna’s LAE102, a first-in-class monoclonal antibody targeting the ...